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Chinese ancient philosophy describes divers concepts such
as Qi (spirit or energy) and the ﬁve natural elements (ﬁre,
earth, water, wood and metal) that along with the Yin and
yang principle (Xu et al., 2011, 2013; Zeng et al., 2013) repre-
sent the fundamental bases of Traditional Chinese medicines
(TCM) theories that consider the unbalances in the body as
the pathological state and thus, rebalancing the body as rem-
edy. From a therapeutic viewpoint, TCM have always beneﬁt-
ted from natural products, including plants, animals and
minerals. TCM are based on different principles such as the
Doctrine of Signatures, that thrived particularly during the
Middle Ages, and it supposes a relation between the plant‘s
shape, structure, biological behavior and the symptoms of
the disease for which this plant could represent a remedy
(Richardson-Boedler, 1999). Based on simple empiric observa-
tions (Ho, 1993), but also on religious or philosophical beliefs
in some cases, the selection of useful natural drugs is a process
that has taken centuries and has required cumulative efforts of
many generations to ﬁnd out the most efﬁcient therapeutic ap-
proaches for each health problem. Yet, TCM have succeeded
in treating many diseases, however have also failed to treat
others and have even been toxic in other cases.
Chinese scientists, as well as international researchers,
working on TCM and more generally on natural products,
have been continuously trying to map the ‘‘Pharmacological
Puzzle’’ of TCM (Liu et al., 2013a; Song et al., 2013; Li and
Zhang, 2013), especially with the standards and requirements
of modern pharmacology and the divers national, regional
and international regulations that put conditions for any prod-
uct or molecule before it can be designed as ‘‘Drug’’ or ‘‘Med-
icine’’ within both a legal and therapeutic context. The main
obstacle that TCM progress faces is that many products are
still a part of the ethnopharmacology and have not switched
yet into the modern pharmacology.The main research ﬁeld that might solve this issue remains
the pharmacognosy since it is the science that mainly combines
a scientiﬁc precise description of the phytochemical constitu-
ents and their pharmacodynamic activity. Importantly, for a
product or a molecule to be considered as ‘‘Drug’’ or ‘‘Medi-
cine’’ biological, chemical, pharmacological and toxicological
proﬁles need to be established, which requires the implication
of divers research ﬁelds, such as biochemistry, molecular biol-
ogy, cytology and molecular pharmacology, that constitute to-
gether the bridge we are in need of to move from TCM as
‘‘Ehnopharmacology’’ to modern therapy with a full Pharma-
cological proﬁle. Indeed, the data we have now are very
encouraging (Li and Zhang, 2013; Boubertakh et al., 2013;
Liu et al., 2013b; Wang et al., 2013a) and the future of TCM
appears highly promising. TCM constitute a gargantuan ther-
apeutic dictionary, within which each word needs a ‘‘modern
pharmacological deﬁnition’’ to be recognized as a ‘‘modern
therapy’’. The basic processes consist on selecting TCM known
for their ethnopharmacological use, and after a phytochemical
study, selected compounds would go through in vitro then
in vivo pharmacological and toxicological investigations. The
ﬁnal step would be clinical studies (Pengfei et al., 2013; Liu
et al., 2014) to conﬁrm the ﬁnal pharmaco-toxicological proﬁle
of the TCM and their active ingredients.
Importantly, the modern pharmacology has identiﬁed the
G protein coupled receptor as an extremely important target
(Emery, 2013; Ghanemi, 2015; Ghanemi et al., 2013) especially
within the nervous system on one hand (Millar et al., 2012;
Ghanemi, 2014b).On the other hand, the chemostructural sim-
ilarities that exist between some phytochemical compounds
and the endogenous neurotransmitters have encouraged more
investigations toward the discovery of TCM derivatives and
extracts to treat many diseases, such as neurological disorders
(Wang et al., 2013) including schizophrenia and Parkinson’s
diseases, which have divers neurotransmitters implicated with-
in the underlying patho-mechanisms (Weickert et al., 2013;
Ghanemi, 2013). The use of developed cellular and animal
models (Ghanemi, 2014a; Reddy and McWeeney, 2006;
Chen et al., 2013) for disease studies is still highly required
for further elucidation of TCM therapeutic effects.
These bridges linking TCM to modern pharmacology have
beneﬁcial impacts on other ﬁelds such as cosmetology. Indeed,
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proach, and here we mention the efﬁcient volcanic mud, which
is effective in skin whitening. Furthermore, it has been also
found out that Nigella glandulifera Freyn et Sint seeds contain
ingredients that have melanogenesis inhibition activity
(Nguyen et al., 2007). These two natural products are both
black, and they both have a skin whitening effect, and this
may, probably according to the Doctrine of Signatures,
encourage focusing more on black drugs when looking for skin
whitening effect, as this would save time during primary
investigations. Yet, it remains important to follow the modern
recognized methods and techniques to study the pharmacody-
namics, toxicology, clinic and other aspects of the TCM. For
instance, after identiﬁcation of this activity in N. glandulifera
seeds, and the isolation of the active ingredient, that is dioctyl
phthalate, it has been classiﬁed as an endocrine disrupter and
its use was prohibited (Sekiguchi et al., 2006; Tickner et al.,
2001). This example may apply for any natural product
showing any potential to be active against any disease before
further necessary scientiﬁc investigations, and this would help
to expedite the progress of drug discovery toward a modern
pharmacological use of the TCM.Acknowledgment
Abdelaziz Ghanemi is the recipient of a 2013 CAS-TWAS
President’s Postgraduate Fellowship.
References
Boubertakh, B., Liu, X.-G., Cheng, X.-L., Li, P., 2013. A spotlight on
chemical constituents and pharmacological activities of Nigella
glandulifera Freyn et Sint seeds. J. Chem. 2013, 12. Article ID
820183. http://dx.doi.org/10.1155/2013/820183.
Chen, M., Kretzschmar, D., Verdile, G., Lardelli, M., 2013. Chapter
25 –0 models of Alzheimer’s disease. In: Conn, P.M. (Ed.), Animal
Models for the Study of Human Disease. Academic Press, Boston,
pp. 595–632.
Emery, A.C., 2013. Chapter sixteen – catecholamine receptors:
prototypes for GPCR-based drug discovery. In: Lee, E.E. (Ed.),
Advances in Pharmacology, Academic Press, pp. 335–356.
Ghanemi, A., 2013. Schizophrenia and Parkinson’s disease: selected
therapeutic advances beyond the dopaminergic etiologies. Alexan-
dria J. Med. 49 (4), 287–291. http://dx.doi.org/10.1016/
j.ajme.2013.03.005.
Ghanemi, A., He, L., Yan, M., 2013. New factors inﬂuencing G
protein coupled receptors’ system functions. Alexandria J. Med. 49
(1), 1–5.
Ghanemi, A., 2014a. Biological properties and perspective applications
of ‘‘Bio-neuter’’ chemicals? Saudi Pharm. J. 22 (1), 1–2.
Ghanemi, A., 2014b. Psychiatric neural networks and neuropharma-
cology: selected advances and novel implications. Saudi Pharm. J.
22 (2), 95–100.
Ghanemi, A., 2015. Targeting G protein coupled receptor-related
pathways as emerging molecular therapies. Saudi Pharm. J. 23 (2),
115–129.
Ho, Z.C., 1993. Principles of diet therapy in ancient Chinese medicine:
‘Huang Di Nei Jing’. Asia Pac. J. Clin. Nutr. 2 (2), 91–95.
Li, S., Zhang, B., 2013. Traditional Chinese medicine network
pharmacology: theory, methodology and application. Chin. J.
Nat. Med. 11 (2), 110–120.
Liu, J., Pei, M., Zheng, C., Li, Y., Wang, Y., Lu, A., Yang, L., 2013a.
A Systems-pharmacology analysis of herbal medicines used in
health improvement treatment: predicting potential new drugs andtargets. Evid. Based Complement. Altern. Med. 2013. http://
dx.doi.org/10.1155/2013/938764.
Liu, W., Jiang, H.L., Mao, B., 2013b. Chinese herbal medicine for
postinfectious cough: a systematic review of randomized controlled
trials. Evid. Based Complement. Altern. Med. 2013. http://
dx.doi.org/10.1155/2013/906765.
Liu, X., Liu, L., Chen, P., Zhou, L., Zhang, Y., Wu, Y., Jiang, L.,
Cheng, D., Huang, W., Yi, D., 2014. Clinical trials of traditional
Chinese medicine in the treatment of diabetic nephropathy––a
systematic review based on a subgroup analysis. J. Ethnopharma-
col. 151 (2), 810–819. http://dx.doi.org/10.1016/j.jep.2013.11.028.
Millar, R.P., Newton, C.L., Roseweir, A.K., 2012. Chapter 2 –
neuroendocrine GPCR signaling. In: Fink, G., Pfaff, D.W., Levine,
J.E. (Eds.), Handbook of Neuroendocrinology. Academic Press,
San Diego, pp. 21–53.
Nguyen, D.T., Nguyen, D.H., Lyun, H.L., Lee, H.B., Shin, J.H., Kim,
E.K., 2007. Inhibition of melanogenesis by dioctyl phthalate
isolated from Nigella glandulifera Freyn. J. Microbiol. Biotechnol.
17 (10), 1585–1590.
Pengfei, L., Xing, L., Yanming, X., Zhiguo, W., 2013. The importance
and necessity of establishing technical speciﬁcations for the
registration of traditional Chinese medicine clinical studies. J.
Altern. Complement. Med. 20 (1), 65–66. http://dx.doi.org/
10.1089/acm.2013.0353.
Reddy, P.H., McWeeney, S., 2006. Mapping cellular transcriptosomes
in autopsied Alzheimer’s disease subjects and relevant animal
models. Neurobiol. Aging 27 (8), 1060–1077.
Richardson-Boedler, C., 1999. The Doctrine of Signatures: a historical,
philosophical and scientiﬁc view (I). Br. Homoeopathy J. 88 (4),
172–177.
Sekiguchi, S., Ito, S., Suda, M., Honma, T., 2006. Involvement of
thyroxine in ovarian toxicity of di-(2-ethylhexyl) phthalate. Ind.
Health 44 (2), 274–279.
Song, J., Zhang, F., Tang, S., Liu, X., Gao, Y., Lu, P., Wang, Y.,
Yang, H., 2013. A module analysis approach to investigate
molecular mechanism of TCM formula: a trial on Shu-feng-jie-du
formula. Evid. Based Complement. Altern. Med. 2013. http://
dx.doi.org/10.1155/2013/731370.
Tickner, J.A., Schettler, T., Guidotti, T., McCally, M., Rossi, M.,
2001. Health risks posed by use of di-2-ethylhexyl phthalate
(DEHP) in PVC medical devices: a critical review. Am. J. Ind. Med.
39 (1), 100–111.
Wang, J., Cui, M., Jiao, H., Tong, Y., Xu, J., Zhao, Y., Han, M., Liu,
J., 2013a. Content analysis of systematic reviews on the effective-
ness of traditional Chinese medicine. J. Tradit. Chin. Med. 33 (2),
156–163.
Wang, Z., Wan, H., Li, J., Zhang, H., Tian, M., 2013b. Molecular
imaging in traditional Chinese medicine therapy for neurological
diseases. BioMed. Res. Int. 2013. http://dx.doi.org/10.1155/2013/
608430.
Weickert, T.W., Mattay, V.S., Das, S., Bigelow, L.B., Apud, J.A.,
Egan, M.F., Weinberger, D.R., Goldberg, T.E., 2013. Dopamin-
ergic therapy removal differentially effects learning in
schizophrenia and Parkinson’s disease. Schizophr. Res. 149 (1–3),
162–166.
Xu, W.-R., Lin, H.-S., Chen, X.-Y., Zhang, Y., 2011. Yin-Yang
balance therapy on regulating cancer stem cells. J. Tradit. Chin.
Med. 31 (2), 158–160.
Xu, Y., Weyman, Philip D., Umetani, M., Xiong, J., Qin, X., Xu, Q.,
Iwasaki, H., Johnson, Carl H., 2013. Circadian Yin-Yang regula-
tion and its manipulation to globally reprogram gene expression.
Curr. Biol. 23 (23), 2365–2374.
Zeng, L.-N., Ma, Z.-J., Zhao, Y.-L., Zhang, L.-D., Li, R.-S., Wang,
J.-B., Zhang, P., Yan, D., Li, Q., Jiang, B.-Q., Pu, S.-B., Lu¨, Y.,
Xiao, X.-H., 2013. The protective and toxic effects of rhubarb
tannins and anthraquinones in treating hexavalent chromium-
injured rats: the Yin/Yang actions of rhubarb. J. Hazard. Mater.
246–247, 1–9.
332 Letter to the EditorAbdelaziz Ghanemi 1
Key Laboratory of Brain and Cognitive Sciences and Key
Laboratory of Animal Models and Human Disease Mechanisms,
Kunming Institute of Zoology, Chinese Academy of Sciences,
No. 32 Jiaochang Donglu, Kunming 650223, Yunnan Province,
PR China
University of Chinese Academy of Sciences,
Beijing 10049, China
E-mail address: ghanemiabdelaziz@hotmail.comBesma Boubertakh 1
State Key Laboratory of Natural Medicines, China Pharma-
ceutical University, No. 24 Tongjiaxiang, Nanjing 210009,
Jiangsu Province, PR China
E-mail address: www.boubertakhbesma@gmail.comReceived 21 December 2013; accepted 15 February 2014
Available online 7 March 20141
Two authors contributed equally.
